Article

Alimera Sciences and Emory University in exclusive agreement for treatments using antioxidants

Atlanta-Alimera Sciences and Emory University will join together in an agreement to research oxidative stress management. The goal in this endeavor is to treat ophthalmic disease by reducing reactive oxygen species (ROS).

Atlanta-Alimera Sciences and Emory University will join together in an agreement to research oxidative stress management. The goal in this endeavor is to treat ophthalmic disease by reducing reactive oxygen species (ROS).

This agreement exclusively allows Alimera to license a unique class of compounds, which are NADPH oxidase inhibitors, as a potential treatment for conditions such as the dry form of age-related macular degeneration (AMD), specifically the late stage of this condition known as geographic atrophy.

Evidence verifies oxidative stress as a key aspect in both disease development and progression. The increased levels of ROS, which result from oxidative stress, also contribute to certain pathologic conditions, including dry AMD.

Alimera has an exclusive worldwide license for the NADPH oxidase inhibitor for ophthalmic indications. Also included in the agreement is an exclusive right to sublicense in ophthalmology and the exclusive option for non-ophthalmic use. Alimera will be in charge of development and commercialization, and Emory will receive milestone payments and royalties from net sales.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.